首页 > 资讯 > 传播动力学模型在HPV疫苗经济学评价中应用

传播动力学模型在HPV疫苗经济学评价中应用

泰然健康网
2024-12-16 06:20

摘要: 介绍传播动力学模型在HPV疫苗药物经济学评价中的应用和计算方法，以期为更好的HPV疫苗经济性评价提供参考。将人群分为n个年龄组和L个性活动层次，建立常微分方程组模拟HPV16/18两种病毒感染在人群中的传播和相关疾病的发生，并结合二价疫苗接种的保护效率对疾病预防健康产出进行评估。传播动力学模型是动态进展模型，较Markov等静态进展模型模拟结果更符合实际，但也因为需要参数多，且部分关键参数在我国暂无大规模人群调研数据，因此用于经济学评价时证据质量受到一定影响。在HPV疫苗等传播性疾病干预产品的经济性评价中采用传播动力学模型以获取更精确的证据，在目前参数不全的情况下，建议暂时以邻国数据等方式替代。

Abstract: To provide a reference for economic evaluation on human papillomavirus (HPV) vaccine vaccination, we briefly introduced the application of transmission dynamics model in HPV vaccine vaccination economic evaluation and related calculation methods. In the transmission dynamics model-based evaluation on vaccination of bivalent HPV vaccine, the population is divided into various age groups and individual activity levels; an ordinary differential equation set is established to simulate the transmission of HPV16/18 virus infection in the population and the occurrence of related diseases; and the health output of disease prevention is calculated in combination with the protection efficiency of the vaccine. The transmission dynamics model is a dynamic progress model, which is more realistic than the simulation results of static progress models such as Markov. However, due to the lack of some key parameters and large-scale population survey data in China, the quality of the economic evaluation on HPV vaccine vaccination is affected to some extent. Considering on the absence of some parameters for the evaluation nowadays, some data from other countries could be utilized in transmission dynamics model-based economic evaluation on HPV vaccine vaccination to obtain more accurate analysis results.

[1]

Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses[J]. PLoS Medicine, 2006, 3(5): e138. DOI: 10.1371/journal.pmed.0030138

[2] 王玉, 陈姗姗, 傅新楚. 传播动力学模型回顾与展望[J]. 应用数学与计算数学学报, 2018, 32(2): 267 – 294. DOI: 10.3969/j.issn.1006-6330.2018.02.008 [3]

Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease[J]. Epidemio-logic Reviews, 2006, 28(1): 88 – 100. DOI: 10.1093/epirev/mxj006

[4] 郄素会. 宫颈癌疫苗用于18~25岁中国女性预防宫颈癌的药物经济学评价[J]. 临床医药文献电子杂志, 2017, 4(48): 9342 – 9343, 9345. DOI: 10.3877/j.issn.2095-8242.2017.48.025 [5] 张倩. 子宫颈癌筛查的风险分流及疫苗的卫生经济学评价研究[D]. 北京: 北京协和医学院, 2017. [6] 孙雨欣, 刘永军, 刘通. 宫颈癌疫苗用于18~25岁中国女性预防宫颈癌的药物经济学评价[J]. 中国循证医学杂志, 2017, 17(1): 102 – 107. DOI: 10.7507/1672-2531.201610004 [7] 莫秀婷. 我国宫颈癌预防策略的经济学评价[D]. 济南: 山东大学, 2015. [8] 刘怡君. HPV-16/18预防性疫苗的接种年龄对其预防子宫颈癌作用的卫生经济学研究[D]. 大连: 大连医科大学, 2015. [9] 宋晓彬, 赵勤俭, 周鼒, 等. 二价HPV疫苗接种策略的卫生经济学评估: 基于动态模型[J]. 中华预防医学杂志, 2017, 51(9): 814 – 820. DOI: 10.3760/cma.j.issn.0253-9624.2017.09.008 [10]

Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies[J]. Emerging Infectious Disease, 2007, 13(1): 28 – 41. DOI: 10.3201/eid1301.060438

[11]

Kermack WO, McKendrick AG. Contributions to the mathematical theory of epidemics: V. Analysis of experimental epidemics of mouse-typhoid; a bacterial disease conferring incomplete immu-nity[J]. Epidemiology and Infection, 1939, 39(3): 271 – 288.

[12]

Kermack WO, McKendrick AG. Contributions to the mathematical theory of epidemics-II. The problem of endemicity[J]. Bulletin of Mathematical Biology, 1991, 53(1): 57 – 87.

[13]

Wolff E, Elfström KM, Haugen Cange H, et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour[J]. Vaccine, 2018, 36(34): 5160 – 5165. DOI: 10.1016/j.vaccine.2018.07.018

[14]

Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination Programmes[J]. PharmacoEconomics, 2008, 26(3): 191 – 215. DOI: 10.2165/00019053-200826030-00004

[15]

Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventative strategies against human papillomavirus-related disease in developed countries[J]. Vaccine, 2012, 30 Suppl 5: F157 – F167.

[16]

Tay SK, Hsu TY, Pavelyev A, et al. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis[J]. BJOG: An International Journal of Obstetrics and Gynaecology, 2018, 125(4): 478 – 486. DOI: 10.1111/1471-0528.15106

[17]

Damm O, Horn J, Mikolajczyk RT, et al. Cost-effectiveness of human papillomavirus vaccination in Germany[J]. Cost Effective-ness and Resource Allocation, 2017, 15: 18. DOI: 10.1186/s12962-017-0080-9

[18]

Largeron N, Petry KU, Jacob J, et al. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany[J]. Expert Review of Pharmacoe-conomics and Outcomes Research, 2017, 17(1): 85 – 98. DOI: 10.1080/14737167.2016.1208087

[19]

Mennini FS, Bonanni P, Bianic F, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy[J]. Cost Effectiveness and Resource Allocation, 2017, 15(1): 11. DOI: 10.1186/s12962-017-0073-8

[20]

Tang CH, Cheng WF, Jiang JH, et al. Cost-effectiveness analysis of human papillomavirus vaccination in adolescent girls in Taiwan[J]. Asian Pacific Journal of Cancer Prevention, 2019, 20(5): 1377 – 1387. DOI: 10.31557/APJCP.2019.20.5.1377

[21] 张师前, 王凯, 张远丽. HPV疫苗在中国的应用现状[J]. 中国实用妇科与产科杂志, 2019, 35(10): 1090 – 1095. [22] 国家药品监督管理局. 首个国产重组人乳头瘤病毒疫苗获批上市[EB/OL]. [2020 – 01 – 03]. http://www.nmpa.gov.cn/WS04/CL2056/373049.html. [23]

Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5[J]. Value in Health, 2012, 15(6): 828 – 834. DOI: 10.1016/j.jval.2012.06.011